The range of neurological syndromes associated with glutamic acid decarboxylase antibodies
- Authors: Krasnov M.Y.1, Pavlov E.V.1, Ershova M.V.1, Timerbaeva S.L.1, Illarioshkin S.N.1
-
Affiliations:
- Research Center of Neurology
- Issue: Vol 9, No 4 (2015)
- Pages: 37-41
- Section: Original articles
- URL: https://ogarev-online.ru/2075-5473/article/view/124645
- DOI: https://doi.org/10.17816/psaic82
- ID: 124645
Cite item
Full Text
Abstract
Neurological syndromes caused by production of antibodies to glutamic acid decarboxylase (GAD65) are a relatively new area of modern clinical neurology, which is of great theoretical and practical interest. High titer of identified antibodies is a not always specific, but highly sensitive, marker for autoimmune CNS disorders. The authors present their own clinical observations and an analysis of the literature on a wide phenotypic range of GAD65-associated pathologies.
About the authors
M. Yu. Krasnov
Research Center of Neurology
Email: merritt.kraut@gmail.com
Russian Federation, Moscow
E. V. Pavlov
Research Center of Neurology
Email: merritt.kraut@gmail.com
Russian Federation, Moscow
Margarita V. Ershova
Research Center of Neurology
Email: merritt.kraut@gmail.com
Russian Federation, Moscow
Sofiya L. Timerbaeva
Research Center of Neurology
Email: merritt.kraut@gmail.com
Russian Federation, Moscow
Sergey N. Illarioshkin
Research Center of Neurology
Author for correspondence.
Email: merritt.kraut@gmail.com
ORCID iD: 0000-0002-2704-6282
D. Sci. (Med.), Prof., Corr. Member of the Russian Academy of Sciences, Deputy Director, Head, Department for brain research
Russian Federation, MoscowReferences
- Каламкарян А.А., Мордовцев В.Н., Трофимова Л.Я. Клиническая дерматология. Редкие и атипичные дерматозы. Ереван: Айастан,1989.
- Краснов М.Ю., Тимербаева С.Л., Иллариошкин С.Н. Генетика наследственных форм дистонии. Анн. клин. и эксперим. неврол. 2013; 2: 55–62.
- Мальмберг С.А., Дадали Е.Л., Жумаханов Д.Б. и др. Синдром ригидного человека с дебютом в грудном возрасте. Нервно-мышечные болезни. 2015; 2: 38–43.
- Alexopoulos H., Dalakas M.C. A clinical update on the immunopathogenesis of Stiff Person Syndrome. Eur. J. Clin. Invest. 2010; 40: 1018–1025.
- Arino H., Gresa-Arribas N., Blanco Y. et al. Cerebellar ataxia and glutamic acid decarboxylase antibodies: Immulologic profile and longterm effect of immunotherapy. JAMA Neurol. 2014; 71: 1009–1016.
- Boronat A., Sabater L., Saiz A. et al. GABAB receptor antibodies in limbic encephalitis and anti-GAD–associated neurologic disorders. Neurology. 2011; 76: 795–800.
- Braun J., Sieper J. Ankylosing spondylitis. Lancet. 2007; 369 (9570): 1379–1390.
- Chen Y.-T. Glycogen storage diseases. In: Scriver C.R., Beaudet A.L., Sly W.S., Valle D. (eds). The Metabolic and Molecular Bases of Inherited Disease. Vol. I. NY: McGraw-Hill, 2001: 1537–1551.
- Dayalu P., Teener J.W. Stiff Person syndrome and other anti-GADassociated neurologic disorders. Semin Neurol. 2012; 32: 544–549.
- Drost G., Verrips A., Hooijkaas Н. et al. Glutamic acid decarboxylase antibodies in Satoyoshi syndrome. Ann. Neurol. 2004; 55: 450–451.
- Ehlayel M.S., Lacassie Y. Satoyoshi syndrome: an unusual postnatal multisystemic disorder. Am. J. Med. Genet. 1995; 57: 620-5.
- Graus F., Delattre J.Y., Antoine J.C. et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J. Neurol. Neurosurg. Psychiatry. 2004; 75: 1135–1140.
- Gultekin S.H. Recent developments in paraneoplastic disorders of the nervous system. Surg. Pathol. Clin. 2015; 8: 89–99.
- Hadjivassiliou M., Sanders D.S., Woodroofe N. et al. Gluten ataxia. Cerebellum. 2008; 7: 494–498.
- Honnorat J., Saiz A., Giometto B. et al. Cerebellar ataxia with antiglutamic acid decarboxylase antibodies. Arch. Neurol. 2001; 58: 225–230.
- Kono S., Miyajima H., Sugimoto M. et al. Stiff-person syndrome associated with cerebellar ataxia and high glutamic acid decarboxylase antibody titer. Intern Med. 2001; 40: 968–971.
- Kuchling J., Shababi-Klein J., Nümann A. et al. GAD antibody-associated late-onset cerebellar ataxia in two female siblings. Case Rep. Neurol. 2014; 6: 264–270.
- Rakocevic G., Floeter M.K. Autoimmune stiff person syndrome and related myelopathies: Understanding of electrophysiological and immunological processes. Muscle Nerve. 2012; 45: 623–634.
- Rüegg S.J., Steck A.J., Fuhr P. Levetiracetam improves paroxysmal symptoms in a patient with stiff-person syndrome. Neurology. 2004; 62: 338.
- Saiz A., Blanco Y., Sabater L. et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008; 131: 2553–2563.
- Sharma B., Nagpal K., Prakash S. et al. Anti-GAD negative stiff person syndrome with a favorable response to intravenous methylprednisolone: An experience over evidence. Neurol India. 2014; 62: 76–77.
- Ueno S., Miyamoto N., Shimura H. et al. Successful immune moderation treatment for progressive encephalomyelitis with rigidity and myoclonus. Intern. Med. 2015; 54: 219–221.
- Vulliemoz S., Vanini G., Truffert A. et al. Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. BMJ Case Rep. 2009; 2009: bcr09.2008.0977.
- Wenninger S., Schoser B. The spectrum of neuromyotonia: clinics, therapy and outcome. Fortschr. Neurol. Psychiatr. 2015; 83: 457–462.
- Wu Y., Weber J.L., Vladutiu G.D., Tarnopolsky M.A. Six novel mutations in the myophosphorylase gene in patients with McArdle disease and a family with pseudo-dominant inheritance pattern. Mol. Genet. Metab. 2011; 104: 587–591.
Supplementary files
